1 / 8

Lutetium Therapy for Metastatic Castration-Resistant Prostate Cancer Treatment in India

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.<br>

ManavSadhwani
Download Presentation

Lutetium Therapy for Metastatic Castration-Resistant Prostate Cancer Treatment in India

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lutetium (Lu 177) PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer Treatment

  2. Several studies and clinical trials have shown that men with advanced prostate cancer have responded extremely well to Lu177 PSMA Therapy – reduced pain, shrunk tumours, and rapid relief from bone pain, thereby leaving them with more energy to enjoy family time.

  3. Studies have also shown that metastatic castration-resistant prostate cancer patients who have progressed after conventional therapies, Lu177 PSMA Therapy has not only delivered high response rates, but low toxic effects, and most importantly reduced pain.

  4. By the second cycle of Lu 177 PSMA Therapy, metastatic castration-resistant prostate cancer patients have experienced a 10 point or more improvement in global health scores.

  5. The adverse effects of Lu 177 PSMA Therapy among metastatic castration-resistant prostate cancer patients, is not only minimal, but also temporary. Dry mouth, tiredness, a transient fall in blood counts and nausea are some of the temporary adverse effects of the therapy.

  6. For more information on the efficacy of Lutetium 177 PSMA Therapy do visit https://nuclearmedicinetherapy.in/treatments/lu-psma-therapy And to Know about Treatment Cost do visit https://nuclearmedicinetherapy.in/blog/lowest-cost-of-lu177-psma-therapy

  7. ABOUT THE CENTRE The team of Nuclear Oncology Experts is a group of dedicated Nuclear Medicine Physicians, Dosimetrists, Radiation Oncologists and Technicians with extensive experience in Nuclear MedicineDiagnostics & Therapies. Operating from the Department of Nuclear Medicine & Molecular Imaging, Fortis Memorial Research Institute (FMRI), Gurgaon in the state of Haryana, India, the centre is the first-of-its-kind dedicated Nuclear Oncology Diagnostic & Therapeutic setup in India. With internationally trained experts and world class facilities, the regimens and protocols followed at the centre are at par with the highest world standards. All cases that come before the team are first discussed in a multi-disciplinary board that includes Medical, Radiation & Surgical Oncologists; Pathologists; Physiologists and Radiologists.

  8. For more information or a free second opinion about your case, please contact Dr. Ishita Sen Director, Department of Nuclear Medicine & Molecular Imaging, Fortis Memorial Research Institute (FMRI) Sector 44, Gurugram, Haryana, INDIA info@nuclearmedicinetherapy.in Call/ Whatsapp: +91 9811 12 7080 www.nuclearmedicinetherapy.in

More Related